AI assistant
Atea Pharmaceuticals, Inc. — Director's Dealing 2024
Feb 3, 2024
33577_dirs_2024-02-02_c3426118-0f86-452e-8c74-e89ee0471246.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2024-01-31
Reporting Person: Foster Wayne (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-31 | Common Stock | M | 33334 | — | Acquired | 33334 | Direct |
| 2024-02-01 | Common Stock | S | 12477 | $3.8394 | Disposed | 20857 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-31 | Restricted Stock Units | $ | M | 33334 | Disposed | Common Stock (33334) | Direct | |
| 2024-01-31 | Stock Option (Right to Buy) | $4.16 | A | 120100 | Acquired | 2034-01-30 | Common Stock (120100) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 15, 2022.
F3: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
F4: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.